<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tscan Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/tscan-therapeutics-inc</link>
<description>Latest news and press releases for Tscan Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tscan-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c7b378dffbe2df11b920.webp</url>
<title>Tscan Therapeutics Inc</title>
<link>https://6ix.com/company/tscan-therapeutics-inc</link>
</image>
<item>
<title>TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting</guid>
<pubDate>Mon, 27 Apr 2026 20:30:00 GMT</pubDate>
<description>WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29ᵗʰ Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually. Poster Presentation Det</description>
</item>
<item>
<title>TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 11:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time. A webcast of the fireside chat will be available on the</description>
</item>
<item>
<title>TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-8</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-8</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced</description>
</item>
<item>
<title>TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-completes-enrollment-in-cohort-c-of-phase-1-allohatm-trial-and-announces-fda-clearance-of-investigational-new-drug-applications-for-heme-candidates-tsc-102-a01-and-tsc-102-a03</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-completes-enrollment-in-cohort-c-of-phase-1-allohatm-trial-and-announces-fda-clearance-of-investigational-new-drug-applications-for-heme-candidates-tsc-102-a01-and-tsc-102-a03</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of</description>
</item>
<item>
<title>TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday,</description>
</item>
<item>
<title>TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-positive-updated-223000522</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-positive-updated-223000522</guid>
<pubDate>Sat, 06 Dec 2025 22:30:00 GMT</pubDate>
<description>Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control arm TSC-101 was well-tolerated with no dose-limiting toxicities observed Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc. on Monday, December 8, at 8:00 a.m. ET WALTHAM, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, I</description>
</item>
<item>
<title>TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-host-virtual-kol-210500147</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-host-virtual-kol-210500147</guid>
<pubDate>Wed, 03 Dec 2025 21:05:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the fu</description>
</item>
<item>
<title>TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-third-quarter-120000677</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-third-quarter-120000677</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA™ Phase 1 heme trial to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of the heme program and initiate preclinical development of in vivo-engineered TCR-T for solid tumors Cash, cash equivalents, and marketable securities expected to fund operations into the second ha</description>
</item>
<item>
<title>TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-participate-guggenheim-2nd-120000375</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-participate-guggenheim-2nd-120000375</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held at the InterContinental Boston in Boston, MA on Wednesday, November 12, 2025 at 10:00 a.m. Easter</description>
</item>
<item>
<title>TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reaches-agreement-fda-113000348</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reaches-agreement-fda-113000348</guid>
<pubDate>Mon, 03 Nov 2025 11:30:00 GMT</pubDate>
<description>Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call a</description>
</item>
<item>
<title>TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-oral-110000014</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-oral-110000014</guid>
<pubDate>Wed, 17 Sep 2025 11:00:00 GMT</pubDate>
<description>Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster</description>
</item>
<item>
<title>TScan Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-participate-upcoming-investor-110000933</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-participate-upcoming-investor-110000933</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference; the fireside chat will be held at the Sheraton New York Times Square on Tuesday, Se</description>
</item>
<item>
<title>TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-second-quarter-110000650</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-second-quarter-110000650</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) thera</description>
</item>
<item>
<title>TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-110000261</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-110000261</guid>
<pubDate>Wed, 28 May 2025 11:00:00 GMT</pubDate>
<description>WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time. A webcast of the presentation will be avail</description>
</item>
<item>
<title>TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-first-quarter-110000049</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-first-quarter-110000049</guid>
<pubDate>Tue, 06 May 2025 11:00:00 GMT</pubDate>
<description>Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a</description>
</item>
<item>
<title>TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-205300207</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-205300207</guid>
<pubDate>Mon, 28 Apr 2025 20:53:00 GMT</pubDate>
<description>WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. Poster Presentatio</description>
</item>
<item>
<title>TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-participate-24th-annual-110000683</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-participate-24th-annual-110000683</guid>
<pubDate>Mon, 31 Mar 2025 11:00:00 GMT</pubDate>
<description>WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the “Eve</description>
</item>
<item>
<title>TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-appoints-commercial-leader-110000702</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-appoints-commercial-leader-110000702</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experienceWALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of exper</description>
</item>
<item>
<title>TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-fourth-quarter-120000620</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-reports-fourth-quarter-120000620</guid>
<pubDate>Wed, 05 Mar 2025 12:00:00 GMT</pubDate>
<description>Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference</title>
<link>https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-120000992</link>
<guid isPermaLink="true">https://6ix.com/company/tscan-therapeutics-inc/news/tscan-therapeutics-announces-upcoming-presentation-120000992</guid>
<pubDate>Thu, 27 Feb 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. A webcast of the presentation wil</description>
</item>
</channel>
</rss>